Genome-wide QTL mapping across three tissues highlights several Alzheimer’s and Parkinson’s disease loci potentially acting via DNA methylation.

Authors

Olena Ohlei, Yasmine Sommerer, Valerija Dobricic, Jan Homann, Laura Deecke, Marcel Schilling, David Bartrés-Faz, Gabriele Cattaneo, Sandra Düzel, Anders M Fjell, Ulman Lindenberger, Álvaro Pascual-Leone, Sanaz Sedghpour Sabet, Cristina Solé-Padullés, Josep M Tormos, Valentin M Vetter, Kristine B Walhovd, Tanja Wesse, Michael Wittig, Andre Franke, Ilja Demuth, Christina M Lill, Lars Bertram

Year of publication

2023

Journal

UKN

Volume

-

Issue

-

ISSN

-

Impact factor

-

Abstract

DNA methylation (DNAm) is an epigenetic mark with essential roles in disease development and predisposition. Here, we created genome-wide maps of methylation quantitative trait loci (meQTL) in three peripheral tissues and used Mendelian randomization (MR) analyses to assess the potential causal relationships between DNAm and risk for two common neurodegenerative disorders, i.e. Alzheimer’s disease (AD) and Parkinson’s disease (PD). Genome-wide single nucleotide polymorphism (SNP; ~5.5M sites) and DNAm (~850K CpG sites) data were generated from whole blood (n=1,058), buccal (n=1,527) and saliva (n=837) specimens. We identified between 11 and 15 million genome-wide significant (p<10-14) SNP-CpG associations in each tissue. Combining these meQTL GWAS results with recent AD/PD GWAS summary statistics by MR strongly suggests that the previously described associations between PSMC3, PICALM, and TSPAN14 and AD may be founded on differential DNAm in or near these genes. In addition, there is strong, albeit less unequivocal, support for causal links between DNAm at PRDM7 in AD as well as at KANSL1/MAPT in AD and PD. Our study adds valuable insights on AD/PD pathogenesis by combining two high-resolution “omics” domains, and the meQTL data shared along with this publication will allow like-minded analyses in other diseases.